Mekonnen Sintayehu, Farris Hawi
Department of Internal Medicine, All Africa Leprosy, Tuberculosis and Rehabilitation Training Center, Addis Ababa, Ethiopia.
Department of Radiology, Addis Ababa University College of Health Science, Addis Ababa, Ethiopia.
Biologics. 2023 Mar 20;17:33-40. doi: 10.2147/BTT.S401289. eCollection 2023.
Ethiopia is attempting to reduce cancer-related morbidity and mortality through a strategic national cancer control plan but according to Globocan 2020, hematologic malignancies particularly leukemia and non-Hodgkin's lymphoma rank among the top five leading causes of new cancer incidence and cause of death among all age groups in both sexes. Hematopoietic stem-cell transplantation (HSCT) is an advanced treatment modality that makes the only effective treatment for cancer and non-cancer-related hematologic diseases unresponsive to conventional therapy. Patients who need stem cell transplants must travel to abroad countries to get the treatment. Meanwhile, the Ethiopian National Specialty and Subspecialty Roadmap sets the goal of establishing HSCT centers in 2020-2029 GC, yet leaders and planners must start taking steps to put the setup in place. Setting up an HSCT facility is challenging for developing countries due to the high costs, limited infrastructure, and need for intensive medical staff training; however, several nations have been able to start successful stem cell transplant programs. This review summarizes the basic steps and requirements of the program in light of guidelines recommendations and lessons learned from other developing countries. It also highlights possible cost-effective opportunities, bottlenecks, and areas that will require work and investment to make the objective reality in Ethiopia. Provides key information to assist administrators and policymakers to set priorities in planning and making informed decisions to establish and maintain the service.
埃塞俄比亚正试图通过一项国家癌症控制战略计划来降低与癌症相关的发病率和死亡率,但根据《全球癌症报告2020》,血液系统恶性肿瘤,尤其是白血病和非霍奇金淋巴瘤,在所有年龄组的男女中,都是新增癌症发病率和死亡原因的五大主要病因之一。造血干细胞移植(HSCT)是一种先进的治疗方式,是唯一对癌症和与癌症无关的血液系统疾病有效的治疗方法,而这些疾病对传统治疗无反应。需要进行干细胞移植的患者必须前往国外接受治疗。与此同时,埃塞俄比亚国家专科和亚专科路线图设定了在公元2020 - 2029年建立造血干细胞移植中心的目标,但领导者和规划者必须开始采取措施来落实这一设置。对于发展中国家来说,建立一个造血干细胞移植设施具有挑战性,因为成本高昂、基础设施有限,且需要对医务人员进行强化培训;然而,一些国家已经能够启动成功的干细胞移植项目。本综述根据指南建议以及从其他发展中国家吸取的经验教训,总结了该项目的基本步骤和要求。它还强调了可能具有成本效益的机会、瓶颈以及需要开展工作和投资的领域,以使埃塞俄比亚的这一目标成为现实。提供关键信息,以协助管理人员和政策制定者在规划中确定优先事项,并做出明智决策,以建立和维持这项服务。